The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Panoramica dello studio
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- (Applicable to healthy subjects only) Healthy subjects not taking any regular prescription medication, without history of allergy, and considered healthy by the physician
- (Applicable to asthma patients only) Patients with atopic asthma diagnosed by a physician with asthma and history of positive skin test(s)
- Physical examination findings within normal limits
- Body mass index (BMI) between 18 and 30, inclusive
Exclusion Criteria:
- Pregnancy and lactation
- Current or previous treatment with a biologic agent (e.g., monoclonal antibody)
- Concurrent disease or condition that would interfere, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to individuals in this study
- History or symptoms of significant psychiatric disease, including but not limited to, depression, schizophrenia, etc.
- History of drug abuse
- Participation in an investigational drug or device trial within the last 30 days prior to screening
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Healthy Volunteers
Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
|
In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. Dilutions of omalizumab and its excipients were in SWFI. |
|
Sperimentale: Allergic Asthma Participants
Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
|
In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. Dilutions of omalizumab and its excipients were made in saline. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants by of Adverse Events Following a Skin Test Procedure
Lasso di tempo: Up to 7 days following skin testing
|
Skin test procedures were skin prick test or intradermal test. The test started with the lowest concentration. If a positive skin reaction was observed, escalation to the next dilution was stopped. Subjects were observed for 20 minutes following each test; subjects were observed for 1 hour after the last intradermal test. Those with a positive response were observed for an additional 6 hours. Severity refers to the intensity of an AE (mild, moderate or severe). Mild is itching or hives, for example. A severe event requires emergency medical treatment and can result in death. |
Up to 7 days following skin testing
|
|
Number of Participants Who Experienced a Positive Skin Reaction (Skin Prick Test)
Lasso di tempo: on the day of skin test
|
For skin prick, positive control (histamine 6 mg/mL) and negative control (saline) were used.
Positive skin reaction was defined as a ≥ 3-mm wheal and/or > 10-mm erythema from negative control.
The skin prick test started with the lowest concentration.
If a positive skin reaction was observed, escalation to the next dilution was stopped.
|
on the day of skin test
|
|
Number of Participants Who Experienced a Positive Skin Reaction (Intradermal Test in Healthy Volunteers)
Lasso di tempo: on the day of skin test
|
For intradermal testing, positive control (histamine 0.1 mg/mL) and negative control (saline) were used.
Positive skin reaction was defined as a ≥ 3-mm wheal and/or > 10-mm erythema from negative control.
The intradermal test started with the lowest concentration.
If a positive skin reaction was observed, escalation to the next dilution was stopped.
|
on the day of skin test
|
|
Number of Participants Who Experienced a Positive Skin Reaction (Intradermal Test in Patients With Allergic Asthma)
Lasso di tempo: on the day of skin test
|
For intradermal testing, positive control (histamine 0.1 mg/mL) and negative control (saline) were used.
Positive skin reaction was defined as a ≥ 3-mm wheal and/or > 10-mm erythema from negative control.
The intradermal test started with the lowest concentration.
If a positive skin reaction was observed, escalation to the next dilution was stopped.
|
on the day of skin test
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Dennis Wong, M.D., Genentech, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Q4465g
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .